IP Library Granted Patent US 11,453,907
Granted Patent B2
US 11,453,907 · App. 16/894,670 · Granted Sep 27, 2022

Crispr effector system based coronavirus diagnostics

Inventors: Feng Zhang (Cambridge, MA); Jonathan Gootenberg (Cambridge, MA); Omar Abudayyeh (Cambridge, MA); Julia Joung (Cambridge, MA); Alim Ladha (Cambridge, MA); Han Altae-Tran (Cambridge, MA); Guilhem Faure (Cambridge, MA)
Assignees: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
C12Q1/6844B01L3/502715B01L7/52C12N9/1276C12N9/22C12N9/78C12Q1/6806B01L2300/0816C12N2310/20C12Q2600/156C12Q2600/16C12Y207/07049G01N2333/165
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,453,907
App. No.
16/894,670
Granted
Sep 27, 2022
Kind
B2
Abstract

Systems and methods for rapid diagnostics related to the use of CRISPR effector systems and optimized guide sequences for detection of coronavirus, including multiplex lateral flow diagnostic devices and methods of use, are provided.

Claims (22)

1. A single reaction composition for detecting the presence of a target polynucleotide in a crude or unprocessed sample, comprising:

a DNA isolation solution capable of isolating target RNA from the crude or unprocessed sample comprising a cell or virus containing a target RNA;

one or more thermostable Cas proteins possessing collateral activity;

at least one guide polynucleotide comprising a sequence capable of binding the target RNA and designed to form a CRISPR-Cas complex with the one or more Cas proteins;

isothermal amplification reagents comprising optimized loop-mediated isothermal amplification (LAMP) primers and amplification reagents; and

a detection construct comprising a polynucleotide component, wherein the one or more Cas proteins exhibit collateral nuclease activity and cleave the polynucleotide component of the detection construct once activated by the target RNA, thereby generating a detectable signal.

2. The composition of claim 1 , wherein at least one of the one or more Cas proteins is a Type V Cas.

3. The composition of claim 2 , wherein the at least one of the one or more Cas proteins is a Cas12b is selected from the group consisting of SEQ ID NOs: 61644-61954.

4. The composition of claim 3 , wherein the Cas12b is Brevibacillus sp. SYSU G02855 (Br) Cas12b or Alicyclobacillus acidiphilus (Aap) Cas 12b.

5. The composition of claim 4 , wherein the at least one guide polynucleotide comprises a sequence selected from SEQ ID NOs: 61957-61961 and 61970-61972.

6. The composition of claim 1 , wherein the optimized LAMP primers are selected from SEQ ID NOs: 1-40, 499 and 61,983-61,988.

7. The composition of claim 1 , wherein the at least one guide polynucleotide is selected from SEQ ID NOs: 40,500-61,643 and SEQ ID NO: 61,989.

8. The composition of claim 7 , wherein the at least one guide polynucleotide comprises a spacer specific for the N gene or S gene of SARS-CoV-2.

9. The composition of claim 1 , further comprising one or more additional additives selected from the group consisting of glycine, taurine, histidine, and combinations thereof.

10. The composition of claim 1 , further comprising RNA binding beads.

11. The composition of claim 1 , wherein the at least one guide polynucleotide is an optimized guide polynucleotide.

12. The composition of claim 1 , further comprising reverse transcriptase.

13. A method for detecting coronavirus in a sample, the method comprising;

distributing a crude or unprocessed sample comprising a cell or virus containing a target RNA or set of said samples into individual discrete volumes, each individual discrete volume comprising the composition of claim 1 ;

incubating the crude or unprocessed sample or set of said samples in the composition of claim 1 at conditions sufficient to isolate the target RNA of the cell or virus via reagents of the DNA isolation solution;

amplifying the isolated target RNA using isothermal amplification, wherein, optionally, isolation of the target RNA from the composition of claim 1 between the incubating and amplifying steps is omitted; and

detecting amplified target RNA by binding of the CRISPR-Cas complex to the amplified target RNA, wherein binding of the amplified target RNA activates cleavage of the detection construct thereby generating a detectable signal.

Assignments (9)
CONFIRMATORY LICENSE Recorded Oct 2, 2023
From: BROAD INSTITUTE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065091/0677 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2021
From: ZHANG, FOR HIMSELF AND AS AGENT OF HOWARD HUGHES MEDICAL INSTITUTE, FENG
To: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 056805/0426 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2021
From: ZHANG, FENG
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 056775/0713 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2020
From: ALTAE-TRAN, HAN
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 054566/0758 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: FAURE, GUILHEM
To: THE BROAD INSTITUTE, INC.
Reel/Frame 053869/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: LADHA, ALIM
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053863/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2020
From: JOUNG, JULIA
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053790/0726 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2020
From: ABUDAYYEH, OMAR
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053145/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2020
From: GOOTENBERG, JONATHAN
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053145/0258 →
Continuity (5)
Provisional Application 63019406 · May 3, 2020
Provisional Application 63018487 · Apr 30, 2020
Provisional Application 62993494 · Mar 23, 2020
Provisional Application 63032470 · May 29, 2020
Related Publication 20210292824A1 · Sep 23, 2021
Cited By (3)
US 12,203,145 US 12,522,863 US 12,709,778